EMMA (Emmaus Life Sciences) Shiller PE Ratio: (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emmaus Life Sciences  (OTCPK:EMMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Emmaus Life Sciences Shiller PE Ratio Related Terms


Emmaus Life Sciences Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Shiller PE Ratio Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmaus Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EMMA vs PCSA, LIMN, KAPA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Shiller PE Ratio falls into.



Emmaus Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Emmaus Life Sciences's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Emmaus Life Sciences's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.02/333.9520*333.9520
=0.020

Current CPI (Jun. 2026) = 333.9520.

Emmaus Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -3.068 241.428 -4.244
201612 -4.140 241.432 -5.727
201703 -3.660 243.801 -5.013
201706 -3.720 244.955 -5.072
201709 -3.696 246.819 -5.001
201712 -3.840 246.524 -5.202
201803 -3.540 249.554 -4.737
201806 -2.760 251.989 -3.658
201809 -1.200 252.439 -1.587
201812 -1.920 251.233 -2.552
201903 -1.620 254.202 -2.128
201906 -1.200 256.143 -1.565
201909 -0.600 256.759 -0.780
201912 0.190 256.974 0.247
202003 0.110 258.115 0.142
202006 -0.190 257.797 -0.246
202009 0.110 260.280 0.141
202012 0.000 260.474 0.000
202103 -0.170 264.877 -0.214
202106 0.050 271.696 0.061
202109 -0.060 274.310 -0.073
202112 -0.140 278.802 -0.168
202203 -0.030 287.504 -0.035
202206 -0.180 296.311 -0.203
202209 -0.010 296.808 -0.011
202212 0.010 296.797 0.011
202303 -0.070 301.836 -0.077
202306 -0.030 305.109 -0.033
202309 -0.010 307.789 -0.011
202312 0.020 306.746 0.022
202403 -0.070 312.332 -0.075
202406 -0.030 314.175 -0.032
202409 0.030 315.301 0.032
202412 -0.030 315.605 -0.032
202503 -0.040 319.799 -0.042
202506 -0.020 322.561 -0.021
202509 -0.030 324.800 -0.031
202512 -0.030 324.054 -0.031
202603 -0.050 330.213 -0.051
202606 0.020 333.952 0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.